Rezolute’s Phase 2 trial of RZ402 shows significant CST reduction in DME patients
Rezolute, Inc. (Nasdaq: RZLT), a leader in the development of novel therapies for serious metabolic and rare diseases, today disclosed promising topline results from its ... Read More